Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines

Y Fukazawa, H Park, MJ Cameron, F Lefebvre… - Nature medicine, 2012 - nature.com
Y Fukazawa, H Park, MJ Cameron, F Lefebvre, R Lum, N Coombes, E Mahyari, SI Hagen…
Nature medicine, 2012nature.com
Live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) remain the most
efficacious of all vaccines in nonhuman primate models of HIV and AIDS, yet the basis of
their robust protection remains poorly understood. Here we show that the degree of LAV-
mediated protection against intravenous wild-type SIVmac239 challenge strongly correlates
with the magnitude and function of SIV-specific, effector-differentiated T cells in the lymph
node but not with the responses of such T cells in the blood or with other cellular, humoral …
Abstract
Live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) remain the most efficacious of all vaccines in nonhuman primate models of HIV and AIDS, yet the basis of their robust protection remains poorly understood. Here we show that the degree of LAV-mediated protection against intravenous wild-type SIVmac239 challenge strongly correlates with the magnitude and function of SIV-specific, effector-differentiated T cells in the lymph node but not with the responses of such T cells in the blood or with other cellular, humoral and innate immune parameters. We found that maintenance of protective T cell responses is associated with persistent LAV replication in the lymph node, which occurs almost exclusively in follicular helper T cells. Thus, effective LAVs maintain lymphoid tissue-based, effector-differentiated, SIV-specific T cells that intercept and suppress early wild-type SIV amplification and, if present in sufficient frequencies, can completely control and perhaps clear infection, an observation that provides a rationale for the development of safe, persistent vectors that can elicit and maintain such responses.
nature.com